Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesc Casellas

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Medicine|April 5, 2019
The experience of inflammatory bowel disease patients with healthcare: A survey with the IEXPAC instrumentIgnacio Marín-Jiménez, Francesc Casellas, Xavier Cortés, et al.
Revista Espanola De Enfermedades Digestivas|July 19, 2019
Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel diseaseFrancesc Casellas, Ester Navarro, Paloma Amil, et al.
Cells|August 13, 2025
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD PatientsLuis Mayorga Ayala, Claudia Herrera-deGuise, Juliana Esperalba, et al.
The Patient|November 16, 2018
Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC ScaleDomingo Orozco-Beltrán, Javier de Toro, María J Galindo, et al.
Journal of Clinical Gastroenterology|May 19, 2009
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's diseaseCarlos Taxonera, Luis Rodrigo, Francesc Casellas, et al.
Gastroenterologia Y Hepatologia|July 13, 2025
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitisFrancesc Casellas, Ana Gutiérrez-Casbas, Cristina Rodríguez, et al.
The Patient|January 31, 2020
A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient PerspectiveEdouard Louis, Juan M Ramos-Goñi, Jesus Cuervo, et al.
Gastroenterologia Y Hepatologia|January 30, 2021
Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel diseaseEster Navarro-Correal, Natalia Borruel, Virginia Robles, et al.
Scientific Reports|May 19, 2026
Fecal microbiome of patients with ulcerative colitis reflects their phenotype and inflammatory levelNicolas Maziers, Emmanuelle Le Chatelier, Florian Plaza Oñate, et al.
Gastroenterologia Y Hepatologia|May 29, 2021
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA studyIgnacio Marín-Jiménez, Manuel Barreiro-de Acosta, María Esteve, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Medicine|April 5, 2019
The experience of inflammatory bowel disease patients with healthcare: A survey with the IEXPAC instrumentIgnacio Marín-Jiménez, Francesc Casellas, Xavier Cortés, et al.
Revista Espanola De Enfermedades Digestivas|July 19, 2019
Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel diseaseFrancesc Casellas, Ester Navarro, Paloma Amil, et al.
Cells|August 13, 2025
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD PatientsLuis Mayorga Ayala, Claudia Herrera-deGuise, Juliana Esperalba, et al.
The Patient|November 16, 2018
Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC ScaleDomingo Orozco-Beltrán, Javier de Toro, María J Galindo, et al.
Journal of Clinical Gastroenterology|May 19, 2009
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's diseaseCarlos Taxonera, Luis Rodrigo, Francesc Casellas, et al.
Gastroenterologia Y Hepatologia|July 13, 2025
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitisFrancesc Casellas, Ana Gutiérrez-Casbas, Cristina Rodríguez, et al.
The Patient|January 31, 2020
A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient PerspectiveEdouard Louis, Juan M Ramos-Goñi, Jesus Cuervo, et al.
Gastroenterologia Y Hepatologia|January 30, 2021
Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel diseaseEster Navarro-Correal, Natalia Borruel, Virginia Robles, et al.
Scientific Reports|May 19, 2026
Fecal microbiome of patients with ulcerative colitis reflects their phenotype and inflammatory levelNicolas Maziers, Emmanuelle Le Chatelier, Florian Plaza Oñate, et al.
Gastroenterologia Y Hepatologia|May 29, 2021
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA studyIgnacio Marín-Jiménez, Manuel Barreiro-de Acosta, María Esteve, et al.
Pageof 9